Monitoring treatment efficacy of GA secondary to AMD using AI-prediction and assessment of intra-individual fellow eye predictors (EURETINA 2024)

Apellis Medical Affairs

Site Access

You must be a Healthcare Professional licensed to practice in Canada to access this site. Please fill in the form below to verify you are a Canadian Healthcare Professional.

"*" indicates required fields

You are entering a website that is technical in nature and was created for scientific exchange with Canadian Healthcare Professionals. The content on this website may include scientific information about investigational compounds or indications that are not approved in Canada. Apellis does not support, endorse or recommend the unapproved use of any compound, including those discussed on this website.

Want to stay connected? To receive updates and information from Apellis, please click here.

If you are a Canadian Healthcare Professional, please submit the form below to access the Apellis Medical Hub.

(*) Required

First Name*

Last Name*

Email*

Province*

Profession*

Health Professional License Number*

By submitting this form I certify that I am a Healthcare Professional licensed to practice in Canada and that the information provided during the registration process is accurate and current.

Email

This field is for validation purposes and should be left unchanged.

If you are not a Canadian Healthcare Professional, you will be redirected to www.apellis.ca

I’m a United States Healthcare Professional

You are now leaving ApellisMedicalHub.ca

You are about to leave ApellisMedicalHub.ca to visit a third-party website. We recommend reviewing the privacy policy and terms & conditions of any site you visit, as Apellis Pharmaceuticals, Inc. is not responsible for their content.

I agree

Monitoring treatment efficacy of GA secondary to AMD using AI-prediction and assessment of intra-individual fellow eye predictors

Report an Adverse Event or Product complaint

Ask a Medical Question

Connect with an MSL